[Table_Reportdate] 2025年06月05日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250605 [table_summary] 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 ➢ 1.英伟达Q1数据中心业务成绩亮眼，美限制EDA龙头对华提供服务——电子行业周报 2025/5/26-2025/6/1 ➢ 2.关注陆家嘴论坛政策发布预期带来的市场情绪催化——非银金融行业周报（20250526- 20250601） ➢ 1.四部门组织开展人力资源服务业与制造业融合发展试点工作 ➢ 2.美国ISM服务业PMI大幅回落，跌至50荣枯线以下 ...

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...

Investment Rating - The report assigns an "Overweight" rating for the food and beverage industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [1][53]. Core Insights - The food and beverage sector experienced a decline of 1.06% last week, slightly outperforming the CSI 300 index by 0.02 percentage points, ranking 27th among 31 sectors [4][9]. - The liquor segment is in a bottoming phase, with a focus on leading companies for recovery. The impact of recent "alcohol bans" is expected to be limited, as business banquets and personal consumption remain the primary drivers of demand [4][9]. - The beer sector is showing signs of improvement as the peak consumption season approaches, with April production figures indicating a 4.8% year-on-year increase [4][23]. - The snack segment is characterized by high growth potential, driven by strong product categories and new distribution channels [4]. - The dairy sector is expected to stabilize as upstream production capacity adjusts, with milk prices anticipated to recover gradually [4]. Summary by Sections 1. Market Performance - The food and beverage sector's performance last week was a decline of 1.06%, with soft drinks showing a notable increase of 9.27% [4][9]. - Top-performing stocks included Junyao Health and Kweichow Moutai, with gains of 38.58% and 32.17% respectively [4][9]. 2. Key Consumer Products and Raw Material Prices 2.1 Liquor Prices - As of June 1, 2025, the price for 2024 Moutai (bottle) is 2,070 CNY, down 50 CNY from the previous month [18]. 2.2 Beer Data - April production for major beer companies reached 2.896 million kiloliters, a 4.8% increase year-on-year [23]. 2.3 Upstream Raw Material Data - As of May 30, 2025, the price of fresh milk is 12.17 CNY per liter, with a year-on-year decrease of 0.49% [25]. 3. Industry Dynamics - Significant growth in wine sales was reported during the JD 618 shopping festival, with red wine sales increasing by 200% year-on-year [50]. - Guangdong province's beer production increased by 1.3% in the first four months of 2025 [50]. 4. Core Company Dynamics - Fuling Zhacai announced a cash dividend of 4.20 CNY per share, totaling 4.85 billion CNY [52]. - Haitian Flavoring announced a cash dividend of 8.60 CNY per share, totaling 47.73 billion CNY [52].

Investment Rating - The report provides a standard investment rating for the basic chemical industry, indicating a cautious outlook due to recent market fluctuations and supply chain disruptions [1]. Core Insights - Japan's Mitsui Chemicals is exiting the NF3 business, which may enhance China's competitiveness in electronic specialty gases, with potential market share expansion [4][10]. - The chlorantraniliprole incident has caused supply disruptions, potentially boosting the market for pesticides and intermediates, with a shift towards high-efficiency, low-toxicity products [4][12]. - The report suggests focusing on key sub-sectors such as integrated refining and petrochemical chains, refrigerant industry leaders, and domestic alternative materials [4][14]. Summary by Sections 1. Industry News and Event Commentary - Mitsui Chemicals' exit from the NF3 business is attributed to rising competition and costs, indicating that Chinese manufacturers may fill the gap and increase exports [10][11]. - The chlorantraniliprole incident is expected to accelerate market consolidation, benefiting companies with technological advantages and regulatory compliance [12][13]. 2. Chemical Sector Weekly Performance - For the week of May 26 to May 30, the Shanghai Composite Index fell by 1.08%, while the Shenwan Petroleum and Petrochemical Index rose by 0.40%, outperforming the market by 1.48 percentage points [15][18]. - The basic chemical index decreased by 0.66%, ranking 23rd among all Shenwan primary industries [15][18]. 3. Key Product Price and Spread Performance - Notable price increases included potassium chloride (up 5.66%) and paraxylene (up 4.94%), while hydrochloric acid saw a significant drop of 28.00% [27][28]. - The price spread for carbon black increased by 31.13%, indicating a tightening supply situation [29][30].

Investment Rating - The report provides a standard investment rating for the basic chemical industry, indicating a cautious outlook due to recent market fluctuations and supply chain disruptions [4]. Core Insights - The exit of Japan's Mitsui Chemicals from the nitrogen trifluoride (NF3) business is expected to enhance China's competitiveness in electronic specialty gases, with potential for increased market share [10][11]. - Supply disruptions from incidents like the chlorantraniliprole event are likely to boost the market outlook for pesticides and intermediates, leading to a potential price recovery in the short term [12][13]. - The report emphasizes the importance of monitoring key sub-sectors and suggests investment opportunities in integrated supply chains and leading companies within the chemical industry [14]. Summary by Sections 1. Industry News and Event Commentary - Mitsui Chemicals announced its exit from the NF3 business, with production ceasing by March 2026, indicating a shift in market dynamics favoring Chinese producers [10]. - A chemical company experienced an explosion, impacting the chlorantraniliprole supply chain, which may lead to a consolidation of market players and a potential price increase for certain pesticide products [12][13]. 2. Chemical Sector Weekly Performance - For the week of May 26 to May 30, the Shanghai Composite Index fell by 1.08%, while the Shenwan Petroleum and Petrochemical Index rose by 0.40%, outperforming the market [15]. - The basic chemical index decreased by 0.66%, ranking 23rd among all Shenwan primary industries [15]. 3. Key Product Price Movements - Notable price increases included potassium chloride (up 5.66%) and paraxylene (up 4.94%), while hydrochloric acid saw a significant drop of 28.00% [27][28]. - The report highlights the price fluctuations of key products, indicating a volatile market environment that could present both risks and opportunities for investors [27][28]. 4. Investment Recommendations - The report suggests focusing on integrated players in the refining-PX-PTA chain, leading fluorochemical companies, and firms in the domestic substitution of new materials [14]. - Specific companies highlighted for potential investment include Hengli Petrochemical, Rongsheng Petrochemical, and various leaders in the semiconductor materials sector [14].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the food and beverage industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [1][53]. Core Insights - The food and beverage sector experienced a decline of 1.06% last week, slightly outperforming the CSI 300 index by 0.02 percentage points, ranking 27th among 31 sectors [4][9]. - The report highlights that the liquor sector is in a bottoming phase, with a focus on leading liquor companies for recovery. The impact of recent "alcohol bans" is expected to be limited, as current consumption is primarily driven by business banquets and personal consumption [4][9]. - The beer sector is showing signs of improvement as the peak demand season approaches, with a reported 4.8% year-on-year increase in beer production for April 2025 [4][23]. - The snack segment is characterized by high growth potential, driven by strong product categories and new distribution channels. The report emphasizes the positive market sentiment surrounding health-oriented products [4][25]. - The dairy sector is expected to stabilize as upstream production capacity adjusts, with milk prices anticipated to recover gradually [4][25]. Summary by Sections 1. Market Performance - The food and beverage sector's performance last week was a decline of 1.06%, with soft drinks showing a notable increase of 9.27% [4][9]. - Top-performing stocks included Junyao Health and Huakai Mountain, with increases of 38.58% and 32.17%, respectively [4][9]. 2. Key Consumption and Raw Material Prices - As of June 1, 2025, the price of 2024 Flying Moutai (original) was 2,135 yuan, down 65 yuan from the previous week [18]. - The beer production for April 2025 was reported at 2.896 million kiloliters, reflecting a year-on-year increase of 4.8% [23]. 3. Industry Dynamics - The report notes a significant increase in wine sales during the JD 618 shopping festival, with red wine sales up 200% year-on-year [50]. - Guangdong province reported a 13.1% year-on-year increase in beer production for April 2025 [50]. 4. Core Company Updates - Fuling Pickled Vegetable announced a cash dividend of 4.20 yuan per 10 shares, totaling 4.85 billion yuan [52]. - Haitian Flavor Industry declared a cash dividend of 8.60 yuan per 10 shares, amounting to 47.73 billion yuan [52].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The railway equipment sector showed significant improvement in Q1 2025, with total revenue growth and enhanced profitability driven by increased fixed asset investment in railways [6][11] - The National Railway Group reported a total revenue of 1,283 billion yuan in 2024, a year-on-year increase of 3.0%, with a net profit of 3.9 billion yuan [6][12] - Passenger and freight demand remains strong, with railway passenger volume reaching 4.31 billion in 2024, up 11.9% year-on-year, and freight volume at 5.18 billion tons, up 2.8% [13][16] - Fixed asset investment in railways was 850.6 billion yuan in 2024, a 11.3% increase, with 3,113 kilometers of new lines put into operation [13][17] - The first batch of high-speed train tenders in 2025 includes 68 sets, indicating ongoing demand for new rolling stock [20] - The maintenance demand for existing trains is increasing as older models enter repair cycles, with significant contracts awarded for high-level repairs [21] - Low-carbon development initiatives are driving the replacement of older diesel locomotives, with a mandate for their retirement by 2035 [22] - The industry is expanding internationally, with major companies actively pursuing overseas projects and collaborations [23][24] Summary by Sections 1. Railway Equipment Sector Tracking - The National Railway Group's financial performance is stable, with a revenue of 1,283 billion yuan in 2024 and a debt ratio of 63.5% [11] - The sector's revenue and profit growth are supported by increasing fixed asset investments and project deliveries [6][26] 2. Market Review - The mechanical equipment sector outperformed the broader market, with a decline of only 0.43% compared to the 1.08% drop in the CSI 300 index [30] 3. Recent Developments - The railway construction investment has slowed down in recent years, but maintenance demand is expected to stabilize [25] - The first quarter of 2025 saw a notable increase in revenue for the railway equipment sector, with a 1.4% growth in total revenue in 2024 [26][31]

Investment Rating - The industry investment rating is "Overweight" [1] Core Viewpoints - The rail transit equipment sector showed significant improvement in Q1 2025, with total revenue growth year-on-year and a notable increase in performance metrics due to rising fixed asset investments in railways [6][11] - The China National Railway Group reported a total revenue of 1,283 billion yuan in 2024, a 3.0% increase year-on-year, with a net profit of 39 billion yuan [6][11] - Passenger travel and freight demand remain strong, with railway fixed asset investment continuing to show positive trends [6][13] - The first batch of high-speed train tenders in 2025 includes 68 sets, indicating ongoing procurement activities that stimulate manufacturing and related industries [6][20] - The maintenance demand for existing trains is increasing as older models enter repair cycles, creating opportunities for related products and services [6][21] - Low-carbon development initiatives are driving the replacement of older diesel locomotives, with a clear timeline for phasing out outdated models by 2035 [6][22] Summary by Sections 1. Rail Transit Equipment Sector Tracking - The rail equipment sector is experiencing a positive trend, with the China National Railway Group's revenue and profit metrics indicating a stable financial foundation for future growth [11][12] - Strong demand for passenger and freight services is reflected in the increasing number of passengers and freight volumes transported by rail [13][19] 2. Market Review - The mechanical equipment sector outperformed the broader market, with a decline of only 0.43% compared to the 1.08% drop in the CSI 300 index [30] 3. Recent Developments in International Cooperation - Chinese rail transit equipment companies are actively pursuing international markets, with significant contracts and collaborations emerging in regions such as the UAE and Kazakhstan [23][24] 4. Financial Performance - The rail transit equipment sector's revenue growth was stable from 2021 to 2024, with a notable increase in Q1 2025 performance metrics driven by fixed asset investments [26][29]